- Home
- TSHA vs AEVA Comparison
TSHA vs AEVA Comparison
Compare TSHA & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- AEVA
- Stock Information
- Founded
- TSHA 2019
- AEVA 2019
- Country
- TSHA United States
- AEVA United States
- Employees
- TSHA N/A
- AEVA N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- AEVA Auto Parts:O.E.M.
- Sector
- TSHA Health Care
- AEVA Consumer Discretionary
- Exchange
- TSHA Nasdaq
- AEVA Nasdaq
- Market Cap
- TSHA 728.4M
- AEVA 808.6M
- IPO Year
- TSHA 2020
- AEVA N/A
- Fundamental
- Price
- TSHA $2.94
- AEVA $13.10
- Analyst Decision
- TSHA Strong Buy
- AEVA Strong Buy
- Analyst Count
- TSHA 7
- AEVA 5
- Target Price
- TSHA $8.71
- AEVA $20.80
- AVG Volume (30 Days)
- TSHA 2.7M
- AEVA 2.7M
- Earning Date
- TSHA 08-12-2025
- AEVA 07-31-2025
- Dividend Yield
- TSHA N/A
- AEVA N/A
- EPS Growth
- TSHA N/A
- AEVA N/A
- EPS
- TSHA N/A
- AEVA N/A
- Revenue
- TSHA $8,098,000.00
- AEVA $13,825,000.00
- Revenue This Year
- TSHA N/A
- AEVA $94.59
- Revenue Next Year
- TSHA N/A
- AEVA $127.05
- P/E Ratio
- TSHA N/A
- AEVA N/A
- Revenue Growth
- TSHA N/A
- AEVA 111.39
- 52 Week Low
- TSHA $1.05
- AEVA $2.36
- 52 Week High
- TSHA $3.31
- AEVA $38.80
- Technical
- Relative Strength Index (RSI)
- TSHA 62.34
- AEVA 30.65
- Support Level
- TSHA $2.69
- AEVA $12.50
- Resistance Level
- TSHA $3.12
- AEVA $14.60
- Average True Range (ATR)
- TSHA 0.17
- AEVA 1.69
- MACD
- TSHA 0.02
- AEVA -0.27
- Stochastic Oscillator
- TSHA 68.97
- AEVA 7.35
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.